<bill session="110" type="s" number="3633" updated="2013-07-19T22:53:29-04:00">
  <state datetime="2008-09-26">REFERRED</state>
  <status>
    <introduced datetime="2008-09-26"/>
  </status>
  <introduced datetime="2008-09-26"/>
  <titles>
    <title as="introduced" type="short">Transparency in Drug Labeling Act</title>
    <title as="introduced" type="official">A bill to amend the Federal Food, Drug, and Cosmetic Act to require country of origin labeling on prescription and over-the-counter drugs.</title>
  </titles>
  <sponsor id="400050"/>
  <cosponsors/>
  <actions>
    <action datetime="2008-09-26">
      <text>Sponsor introductory remarks on measure.</text>
      <reference ref="CR S9715-9716"/>
    </action>
    <action state="REFERRED" datetime="2008-09-26">
      <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
    </action>
  </actions>
  <committees>
    <committee code="SSHR" name="Senate Health, Education, Labor, and Pensions" activity="Referral, In Committee"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Health"/>
    <term name="Commerce"/>
    <term name="Drug industry"/>
    <term name="Drugs"/>
    <term name="Foreign trade and international finance"/>
    <term name="Imports"/>
    <term name="Labeling"/>
  </subjects>
  <amendments/>
  <summary>9/26/2008--Introduced.
Transparency in Drug Labeling Act - Amends the Federal Food, Drug, and Cosmetic Act to deem a drug to be misbranded unless the labeling of such drug lists the identity of the country of manufacture of each active ingredient and each inactive ingredient of the drug, listed in descending order based on the percentage of the number of such ingredients in the final dosage form manufactured in such countries.</summary>
</bill>
